Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Study Overview: This study is testing two drugs, venetoclax and tocilizumab, to find the best dose and side effects in treating a specific type of multiple myeloma, a blood cancer. Venetoclax may help stop cancer cells from growing by blocking a protein they need. Tocilizumab is a special protein that may help stop cancer from spreading and is used to treat side effects from other cancer treatments. The combination is hoped to kill more cancer cells.

• Study Length: Each treatment cycle is 21 days, and you will be followed up for 4 weeks after finishing the study.
• Visits Needed: You will need to visit for intravenous (IV) treatment and take oral medication.
• Risks: Possible side effects and dose-limiting toxicities will be monitored closely.

To join, you must be at least 18 years old, have a type of multiple myeloma that has come back or doesn’t respond to treatment, and have been treated with certain other cancer drugs before. You should not join if you have other uncontrolled health problems or certain infections. Pregnant or breastfeeding women cannot participate. The study aims to find the safest and most effective dose for future use. 🌟